Comparative evaluation of raloxifene versus estrogen: Progestin on symptomatology, endometrium, and lipid profile in postmenopausal women

The objective of the study was to evaluate the effects of raloxifene and estrogen progesterone (E + P) combination on symptoms, endometrium, and lipid profile in postmenopausal women. Ninety healthy postmenopausal women were enrolled and allocated to three groups namely E + P, raloxifene, and controls. These groups were given 0.625 mg conjugated estrogen and 2.5 mg medroxyprogesterone, 60 mg raloxifene and no therapy, respectively. Symptomatology and lipid profile were evaluated at 3, 6, and 12 months. Endometrial thickness was evaluated at 6 and 12 months, and endometrial biopsy was repeated at 12 months. The demographic profile of the women in the three different groups was comparable. In addition, the symptomatology, lipid profile, mean endometrial thickness, and endometrial biopsy categorization were comparable. E + P and raloxifene were equally effective in improving the postmenopausal symptoms and lipid profile. E + P had stimulatory effect on the endometrium, whereas raloxifene was found to be neutral.